AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03285308
Drug: Relamorelin
RxNorm normalized name: Relamorelin
DrugBank: Relamorelin (DB12678)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relamorelin 10 micrograms (μg) injected subcutaneously twice daily.
Trial: NCT04301908
Drug: interferon
RxNorm normalized name: Interferon
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antiviral therapy for patients with chronic hepatitis B and cirrhosis. Antiviral therapies included interferon and / or nucleoside (acid) analogs, and patients who were continuously treated for more than 6 months were included in the study.
Trial: NCT01035983
Drug: Frovatriptan 2.5 mg
RxNorm normalized name: frovatriptan 2.5 MG
DrugBank: Frovatriptan (DB00998)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03283761
Drug: Nab-paclitaxel 150 mg/m^2
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Stage I (N=12), on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
Trial: NCT03283761
Drug: Oxaliplatin 85 mg/m^2
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Stage I (N= 12), on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
Trial: NCT02299115
Drug: Vigabatrin
RxNorm normalized name: Vigabatrin
DrugBank: Vigabatrin (DB01080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antiepileptic
Trial: NCT01459562
Drug: NI-0501
RxNorm normalized name: Toto ni vavalagi oil
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00685672
Drug: adrenalin
RxNorm normalized name: Adrenalin
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: adrenalin 2 microgram pr ml placebo
Trial: NCT01442428
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week
Trial: NCT01442428
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration in this TB population)
Trial: NCT04181723
Drug: Trofinetide
RxNorm normalized name: Trofinetide
DrugBank: Trofinetide (DB06045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trofinetide solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
Trial: NCT00273390
Drug: Remicade (infliximab)
RxNorm normalized name: infliximab Injection [Remicade]
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03603379
Drug: C225-ILs-dox
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: C225-ILs-dox will be administered at a dose of 50 mg/m2. i.v., on day 1 of each cycle, cycle length is 28 days. In total, 4 cycles are planned to be applied.
Trial: NCT03148561
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose vaginally
Trial: NCT03497169
Drug: Lisdexamfetamine Dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients are tested for their normal prescription lisdexamphetamine medication
Trial: NCT00294463
Drug: Tibolone
RxNorm normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00525551
Drug: Acetylcysteine
RxNorm normalized name: Acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg / kg body weight. Drug is dissolved in NaCl to a final volume of 300 mL. This volume is infused starting one hour prior to surgery, and continued 1 hour after the end of surgery.
Trial: NCT00987753
Drug: L-377202
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For each cycle, L-377202 will be administered as a 30-minute infusion every 3 weeks. The starting dose will be 20 mg/m2/week. Doses will be doubled until a patient experiences a greater than or equal to Grade 2 toxicity.
Trial: NCT00635232
Drug: irbesartan
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg (2 x 150 mg capsules) once daily for 12 weeks
Trial: NCT00578669
Drug: Dextrose
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily for 16 weeks
Trial: NCT03277482
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab is given by intravenous infusion every 4 weeks for a maximum of 13 doses over 52 weeks. One cycle is defined as every 4 weeks. Each infusion will take approximately 1 hour.
Trial: NCT03277482
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab is given by intravenous infusion every 4 weeks for a maximum of 4 doses over 16 weeks. One cycle is defined as every 4 weeks. If receiving both durvalumab and tremelimumab for the first 4 cycles, they will be given on the same day. Each infusion will take approximately 1 hour
Trial: NCT00813527
Drug: Lapaquistat acetate and fenofibrate
RxNorm normalized name: simvastatin and fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
Trial: NCT00813527
Drug: Fenofibrate
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
Trial: NCT00164151
Drug: HalfLytely
RxNorm normalized name: HalfLytely and Bisacodyl
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00164151
Drug: Visicol
RxNorm normalized name: Visicol
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00319982
Drug: Diltiazem
RxNorm normalized name: Diltiazem
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained release formulation titrated to a target dose of 360 mg daily, or a maximum of 5 mg/kg/day in pediatric subjects for the duration of the study period
Trial: NCT02741817
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention has been described previously in both arms individually. Group A will receive 20mg of soluble Aspirin and group B with 75mg of soluble Aspirin. As this is a crossover study, all patients will fall under both groups throughout the duration and be un-blinded.
Trial: NCT02351960
Drug: Dexlansoprazole
RxNorm normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole capsules
Trial: NCT02056392
Drug: Selumetinib
RxNorm normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Volunteers will receive 75 mg selumetinib oral dose (Treatment A)
Trial: NCT02056392
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Volunteers will receive 400 mg Moxifloxacin oral dose (Treatment B)
Trial: NCT02056392
Drug: selumetinib placebo
RxNorm normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Volunteers will receive selumetinib placebo oral dose (Treatment C)
Trial: NCT00324480
Drug: alvocidib
RxNorm normalized name: Alvocidib
DrugBank: Alvocidib (DB03496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00324480
Drug: vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00259272
Drug: olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks.
Trial: NCT02565173
Drug: trabodenoson 4.5% BID
DrugBank: Trabodenoson (DB13122)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabodenoson 4.5% administered twice per day in both eyes for 12 weeks.
Trial: NCT02565173
Drug: trabodenoson 6.0% QD
DrugBank: Trabodenoson (DB13122)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabodenoson 6.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.
Trial: NCT02565173
Drug: trabodenoson 3.0% QD
DrugBank: Trabodenoson (DB13122)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabodenoson 3.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.
Trial: NCT02565173
Drug: timolol 0.5% BID
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol 0.5% administered twice per day in both eyes for 12 weeks.
Trial: NCT04142892
Drug: Onapristone
RxNorm normalized name: Onapristone
DrugBank: Onapristone (DB12637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg given orally (PO), twice a day (BID), in a continuous schedule (QD) during 3 weeks (+/-3 days)
Trial: NCT03463382
Drug: Bupivacaine (Block Drug)
RxNorm normalized name: bupivacaine Drug Implant
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0,25% Bupivacaine was used 0,5ml/kg (max. 20cc) for block performances
Trial: NCT00943267
Drug: Drotrecogin alpha
RxNorm normalized name: Drotrecogin Alfa
DrugBank: Drotrecogin alfa (DB00055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drotrecogin alpha is given intrabronchially by bronchoscopy at t=0
Trial: NCT00943267
Drug: Saline (NaCl 0.9%)
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normal saline is given intrabronchially by bronchoscopy at t=0
Trial: NCT03158974
Drug: East Indian Sandalwood Oil Cream
RxNorm normalized name: East Indian lemongrass oil
DrugBank: Lemon (DB10538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream containing 10% East Indian Sandalwood Oil (EISO)/Albuterpenoids
Trial: NCT01094886
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10mg tablet daily, receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement
Trial: NCT04051112
Drug: SCB-313
RxNorm normalized name: SCB-2019
DrugBank: SCB-2019 (DB15805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg group: Intraperitoneal injection single dose on Day 0, safety observation for 7 days, then 3 continuous doses on Day7, Day8, Day9, 21 days for 1 cycle
Trial: NCT00574912
Drug: Insulin Glargine 0.5 u/kg body wt SC
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 8 weeks later, a differing dose (0.5, 1.0, 1.5, 2.0 u/kg body wt.) of Insulin Glargine and monitoring over a 24 hour period each separated by 8 weeks (5 separate study visits)
Trial: NCT00574912
Drug: Insulin Glargine 1.0 u/kg body wt SC
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00574912
Drug: Insulin Glargine 1.5 u/kg body wt SC
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00574912
Drug: Insulin Glargine 2.0 u/kg body wt SC
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01429116
Drug: tasimelteon
RxNorm normalized name: Tasimelteon
DrugBank: Tasimelteon (DB09071)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension
Trial: NCT01325181
Drug: Verteporfin
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: a 6mg/m2 infusion of verteporfin(Visudyne; Novartis)over 10 minutes followed by laser delivery
Trial: NCT01325181
Drug: ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Consecutive intravitreal injection of ranibizumab(Lucentis®, Novartis) 0.5mg/0.05ml for the first 3 months
Trial: NCT00103610
Drug: Granulocyte colony-stimulating factor plus plerixafor
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
Trial: NCT00103610
Drug: Granulocyte colony-stimulating factor plus placebo
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
Trial: NCT00727766
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00362479
Drug: DR-1021
RxNorm normalized name: Dr. Numb
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet daily
Trial: NCT00393965
Drug: MPC-6827
RxNorm normalized name: GIVI-MPC
DrugBank: GIVI-MPC (DB17905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-hour IV infusion given once weekly for 3 consecutive weeks on a 28-day cycle.
Trial: NCT03492827
Drug: chlorhexidine acetate gargle
RxNorm normalized name: Chlorhexidine Acetate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: observe whether it can achieve the effect of preventing postoperative infection
Trial: NCT05896930
Drug: Meropenem 6g IV over 6 hours
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem 6g intravenously over 6 hours once daily on days 1-14.
Trial: NCT05896930
Drug: Ertapenem 1g IM
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ertapenem 1g intramuscularly once daily on days 1-14.
Trial: NCT05896930
Drug: Meropenem 3g IV
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem 3g intravenously twice daily over 60 minutes on days 1-14.
Trial: NCT05896930
Drug: Ertapenem 1g IV
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ertapenem 1g intravenously once daily on days 1-14.
Trial: NCT05896930
Drug: Amoxicillin/CA twice daily
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally 12-hourly on days 1-14.
Trial: NCT05896930
Drug: Meropenem 6g IV over 60 minutes
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem 6g intravenously once daily over 60 minutes on days 1-14.
Trial: NCT05896930
Drug: Rifafour e-275
RxNorm normalized name: E-EPA
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rifafour e-275 will be supplied as fixed dose combination tablets and administered orally once daily for 14 days as The daily dose is dependent on the participants' weight as follows: 40 - 54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets.
Trial: NCT05896930
Drug: Meropenem 4g IV
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem 4g intravenously once daily over 60 minutes on days 1-14.
Trial: NCT05896930
Drug: Amoxicillin/CA once daily
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin/CA 2 tablets x 1000mg/62.5mg orally once daily on days 1-14.
Trial: NCT00378404
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg/m2 IV on days 1, 8, 15 every 28 days for 6 cycles
Trial: NCT02249312
Drug: BIIL 284 BS
RxNorm normalized name: BS-001
DrugBank: BS-001 (DB17415)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02519738
Drug: Silver Nitrate
RxNorm normalized name: Silver Nitrate
DrugBank: Silver nitrate (DB11080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Silver nitrate to be applied 3 times weekly for a period of 3 weeks.
Trial: NCT02519738
Drug: Kenalog (Triamcinolone)
RxNorm normalized name: triamcinolone Injection [Kenalog]
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone will be applied as an ointment to the granulation tissue site three times daily for a total of three weeks.
Trial: NCT02086903
Drug: Ticagrelor 90 mg
RxNorm normalized name: ticagrelor 90 MG
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The subjects administer Ticagrelor 90 mg as loading dose (LD) follow by 90 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Clopidogrel 600 mg as LD follow by 75 mg/day as MD for 5 days).
Trial: NCT02086903
Drug: Clopidogrel 600 mg
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The subjects administer Clopidogrel 600 as loading dose (LD) follow by 75 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Ticagrelor 90 mg/day as LD, follow by 90 mg/day as MD for 5 days).
Trial: NCT00968799
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin is applied as chemotherapy during surgery
Trial: NCT03220347
Drug: CC-90010
RxNorm normalized name: Bet inhibitor cc-90010
DrugBank: Trotabresib (DB17421)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-90010 is an oral, potent and reversible inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins.
Trial: NCT03038308
Drug: Ropinirole
RxNorm normalized name: Ropinirole
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.25mg/day - 6.0mg/day oral non-ergoline dopamine agonist ropinirole
Trial: NCT02516553
Drug: BI 894999
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film-coated tablets
Trial: NCT01584453
Drug: Sodium Nitrite
RxNorm normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A bolus of sodium nitrite solution (1.8 micromol in 10 ml PRe-diluted in 0.9% sodium chloride in a syringe) will be delivered over 30-60 seconds via intracoronary injection initiated during the re-establishment of antegrade epicardial flow with PPCI.
Trial: NCT01584453
Drug: Sodium Chloride Placebo
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The control intervention is a bolus of 0.9% sodium chloride solution (prepared with an identical appearance to the sodium nitrite).
Trial: NCT04642651
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in the dexmedetomidine group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and 1.0 μg/kg dexmedetomidine, in a total volume of 20 ml.
Trial: NCT02516527
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03830827
Drug: Vortioxetine
RxNorm normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 8-week 10-20mg/day vortioxetine; 2-hour MBRP intervention per week in 8 weeks
Trial: NCT01071187
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Varenicline 0,5mg daily on day 1-3, Varenicline 1mg daily on day 4-7 and Varenicline 2mg on day 8-84.
Trial: NCT00049582
Drug: decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01203020
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfex 130 mg/m2 intravenous piggy back (IVPB) for 4 days (Day -6 to -3) pharmacokinetic (PK) samples for Busulfex dose adjustment drawn on Day -6
Trial: NCT01203020
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 40 mg/m2 IVPB for 4 days (Day -6 to -3)